But new research published in JAMA Pediatrics found distinct patterns of long COVID symptoms in young children. Researchers ...

Gilead Sciences Inc. closed 7.92% below its 52-week high of $119.96, which the company achieved on March 10th.

A new injection to prevent HIV is expected to be approved by the U.S. Food and Drug Administration (FDA) later this month. If ...

Later this month, the Food and Drug Administration is widely expected to approve a groundbreaking twice-yearly injection to ...

Autolus Therapeutics plc delivers a breakthrough CAR-T therapy for B-ALL with strong safety/efficacy. Learn more about AUTL ...

While the broader market has struggled with the S&P 500 down 2.4% since December 2024, Gilead Sciences has surged ahead as ...

At Gilead, we’re advancing new ways to help end the HIV epidemic by delivering innovative therapies to those who need them ...

Trastuzumab deruxtecan plus pertuzumab outperformed standard-of-care therapy as first-line treatment for HER2-positive ...

Total gross proceeds of up to $150.0 million before the end of 2026 if all Series B warrants and Series C warrants are ...

Avenzo Therapeutics has commenced the open-label Phase I/II trial of its CDK4 selective inhibitor, AVZO-023, for breast ...

Remdesivir was associated with a significant survival benefit and reduced risk for rehospitalization among inpatients with COVID-19 infection.

Sanofi picked up Blueprint Medicines in a deal worth up to $9.5 billion. Bristol Myers Squibb will pay $1.5 billion upfront ...